PDEX vs. STIM, DRIO, XAIR, TTOO, LYRA, INO, ANGO, UTMD, OBIO, and RCEL
Should you be buying Pro-Dex stock or one of its competitors? The main competitors of Pro-Dex include Neuronetics (STIM), DarioHealth (DRIO), Beyond Air (XAIR), T2 Biosystems (TTOO), Lyra Therapeutics (LYRA), Inovio Pharmaceuticals (INO), AngioDynamics (ANGO), Utah Medical Products (UTMD), Orchestra BioMed (OBIO), and AVITA Medical (RCEL). These companies are all part of the "surgical & medical instruments" industry.
Neuronetics (NASDAQ:STIM) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings.
Pro-Dex received 21 more outperform votes than Neuronetics when rated by MarketBeat users. However, 68.48% of users gave Neuronetics an outperform vote while only 60.74% of users gave Pro-Dex an outperform vote.
Pro-Dex has lower revenue, but higher earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.
Neuronetics has a beta of 2.5, suggesting that its stock price is 150% more volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
In the previous week, Pro-Dex had 1 more articles in the media than Neuronetics. MarketBeat recorded 6 mentions for Pro-Dex and 5 mentions for Neuronetics. Pro-Dex's average media sentiment score of 1.07 beat Neuronetics' score of 1.02 indicating that Neuronetics is being referred to more favorably in the media.
Neuronetics currently has a consensus target price of $8.00, indicating a potential upside of 296.04%. Given Pro-Dex's higher probable upside, research analysts clearly believe Neuronetics is more favorable than Pro-Dex.
53.6% of Neuronetics shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 9.8% of Neuronetics shares are held by insiders. Comparatively, 42.6% of Pro-Dex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Pro-Dex has a net margin of 4.13% compared to Pro-Dex's net margin of -37.61%. Neuronetics' return on equity of 6.50% beat Pro-Dex's return on equity.
Summary
Pro-Dex beats Neuronetics on 10 of the 17 factors compared between the two stocks.
Get Pro-Dex News Delivered to You Automatically
Sign up to receive the latest news and ratings for PDEX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PDEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
